Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial Post author: Post published:December 10, 2024 Post category:uncategorized A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). You Might Also Like Researchers suggest stress hormones explain how obesity causes diabetes November 12, 2024 Study reveals disparities in cleft lip surgery for non-White children November 1, 2024 New Alzheimer’s guidelines provide comprehensive framework for diagnosis December 23, 2024